WallStSmart

Alcon AG (ALC)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 174% more annual revenue ($29.14B vs $10.63B). ALC leads profitability with a 7.7% profit margin vs 3.3%. MDLN trades at a lower P/E of 32.1x. MDLN earns a higher WallStSmart Score of 52/100 (C-).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-24.0%)

Margin of Safety

-24.0%

Fair Value

$64.04

Current Price

$66.81

$2.77 premium

UndervaluedFair: $64.04Overvalued

Intrinsic value data unavailable for MDLN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

MDLN3 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Market CapQuality
$65.23B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

Return on EquityProfitability
3.7%3/10

ROE of 3.7% — below average capital efficiency

Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
32.1x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.794/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Market Cap, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.7x leaves little room for execution misses.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDLN is growing revenue faster at 10.7% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 49/100) and 10.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?